Genetics

The Biology and Diagnosis of Sjögren-Larsson Syndrome

At a Glance

Sjögren-Larsson Syndrome (SLS) is a genetic disorder caused by ALDH3A2 gene mutations, which stop the body from breaking down certain fats. Diagnosis is confirmed through genetic testing, recognizing classic symptoms like dry skin, and finding a unique lipid peak on a brain MRI.

Understanding the biology of Sjögren-Larsson Syndrome (SLS) is like looking at a broken recycling system inside your child’s cells. While the medical terms can be daunting, the underlying cause is a specific genetic “instruction error” that leads to a buildup of toxic substances ^[1].

The Biology: A “Cleanup” Failure

The body uses a specialized enzyme called FALDH (fatty aldehyde dehydrogenase) to break down certain fats ^[2]. In SLS, the instructions for making this enzyme—the ALDH3A2 gene—contain mutations ^[3].

Because SLS is an autosomal recessive condition, it is caused by biallelic mutations ^[4]. This means a child must inherit two copies of the mutated gene—one from each parent—to develop the syndrome ^[5].

When these instructions are broken, the FALDH enzyme doesn’t work. This leads to a toxic “trash” buildup of fatty aldehydes and fatty alcohols ^[6]. These substances are not harmless; they attach themselves to the walls of cells (cell membranes), damaging their integrity ^[7].

In the Skin: This damage blocks the production of essential moisture-locking fats (ceramides), leading to the dry, scaly skin of ichthyosis ^[8].
In the Brain: The buildup disrupts myelin, the fatty insulation that helps nerve signals travel quickly. This damage leads to muscle stiffness and learning challenges ^[9]^[10].

Reading the Medical Reports

You will likely see several technical terms on your child’s diagnostic reports. Here is what they mean in plain language:

Leukoencephalopathy: A broad term for diseases affecting the brain’s “white matter” (the part of the brain made of insulated nerve fibers) ^[11]. In SLS, this shows up on an MRI as symmetrical, bright patches ^[12].
MR Spectroscopy (MRS): A special type of MRI that measures chemicals instead of just taking pictures ^[11]. In SLS, it typically shows a high lipid peak at 1.3 ppm. This is essentially a chemical “snapshot” of the toxic fats building up in the brain tissue ^[10]^[13].
Pathognomonic: A doctor’s way of saying “this symptom is a dead giveaway.” For SLS, the glistening yellow dots in the eyes are considered pathognomonic ^[4].

The Diagnosis: A Completeness Checklist

To definitively diagnose SLS, doctors look for a combination of clinical, chemical, and genetic evidence. Ensure the following have been discussed with your team:

Clinical Evaluation: Documentation of the “classic triad” (skin, movement, and learning symptoms) ^[4].
Genetic Testing: Sequencing of the ALDH3A2 gene to find the two specific mutations ^[5].
Specialized Imaging: A brain MRI and MRS to look for white matter changes and the signature 1.3 ppm lipid peak ^[10]^[11].
Enzymatic Assay (Optional but common): A test usually performed on a small skin sample (cultured fibroblasts) to measure exactly how much FALDH enzyme activity is present ^[14].
Eye Exam: A dilated exam by an ophthalmologist to look for crystalline maculopathy (the yellow dots) ^[15].

Once a diagnosis is confirmed, the next step is establishing a treatment plan. You can read more about this in Managing SLS: Standard of Care and Treatments.

Common questions in this guide

What causes Sjögren-Larsson Syndrome?

Sjögren-Larsson Syndrome is caused by inheriting two mutated copies of the ALDH3A2 gene, one from each parent. This mutation stops the body from making a working FALDH enzyme, leading to a toxic buildup of fats that damages the cells of the skin and brain.

What does an MRI show in a child with Sjögren-Larsson Syndrome?

An MRI typically shows leukoencephalopathy, which appears as symmetrical bright patches in the brain's white matter. A specialized MRI called MR Spectroscopy (MRS) will also reveal a unique chemical lipid peak at 1.3 ppm, confirming the buildup of toxic fats.

What are the glistening yellow dots in my child's eyes?

The glistening yellow dots in the eyes, known as crystalline maculopathy, are a signature sign of Sjögren-Larsson Syndrome. An ophthalmologist will look for these during a dilated eye exam to help confirm the diagnosis.

How is Sjögren-Larsson Syndrome definitively diagnosed?

Diagnosis requires a combination of clinical evaluations, genetic testing to find the ALDH3A2 mutations, and brain imaging like MRI and MRS. Doctors may also perform a dilated eye exam or an enzymatic test on a small skin sample to measure FALDH activity.

What does 'biallelic mutations' mean on my child's genetic report?

Biallelic means your child inherited two copies of the mutated gene—one from each parent. Because Sjögren-Larsson Syndrome is an autosomal recessive condition, both copies of the ALDH3A2 gene must be mutated for a child to develop the syndrome.

Curated prompts to bring to your next appointment.

1.Does my child's genetic report show 'biallelic' mutations, and were these identified as known pathogenic variants in the ALDH3A2 gene?
2.Can you show me the lipid peak at 1.3 ppm on the MR Spectroscopy results and explain how it confirms the metabolic issue?
3.If enzymatic testing was done on skin fibroblasts, what was the percentage of FALDH activity measured compared to normal levels?
4.Are the white matter changes (leukoencephalopathy) on the MRI symmetrical, and how do they correlate with my child's current muscle stiffness?
5.Is there any evidence in my child's results of gray matter involvement, or is the focus entirely on the white matter?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (15)

1
Ciliopathy: Sjögren-Larsson Syndrome.
Tsang SH, Aycinena ARP, Sharma T
Advances in experimental medicine and biology 2025; (1467()):195-196 doi:10.1007/978-3-031-72230-1_36.
PMID: 40736838
2
Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects.
Abdel-Hamid MS, Issa MY, Elbendary HM, et al.
Journal of human genetics 2019; (64(9)):859-865 doi:10.1038/s10038-019-0637-x.
PMID: 31273323
3
Genotype and phenotype variability in Sjögren-Larsson syndrome.
Weustenfeld M, Eidelpes R, Schmuth M, et al.
Human mutation 2019; (40(2)):177-186 doi:10.1002/humu.23679.
PMID: 30372562
4
Comprehensive in silico screening and molecular dynamics studies of missense mutations in Sjogren-Larsson syndrome associated with the ALDH3A2 gene.
Udhaya Kumar S, Thirumal Kumar D, Mandal PD, et al.
Advances in protein chemistry and structural biology 2020; (120()):349-377 doi:10.1016/bs.apcsb.2019.11.004.
PMID: 32085885
5
Compound heterozygous mutations in the ALDH3A2 gene cause Sjögren-Larsson syndrome: a case report.
Liu YD, Lin HJ, Li CY, et al.
The International journal of neuroscience 2020; (130(11)):1156-1160 doi:10.1080/00207454.2020.1716750.
PMID: 31944864
6
Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents.
Rizzo WB, S'aulis D, Dorwart E, Bailey Z
Molecular genetics and metabolism reports 2022; (30()):100839 doi:10.1016/j.ymgmr.2021.100839.
PMID: 35242571
7
Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.
Rizzo WB
Expert opinion on orphan drugs 2016; (4(4)):395-406 doi:10.1517/21678707.2016.1154453.
PMID: 27547594
8
Impaired Skin Barrier Function Due to Reduced ω-O-Acylceramide Levels in a Mouse Model of Sjögren-Larsson Syndrome.
Nojiri K, Fudetani S, Arai A, et al.
Molecular and cellular biology 2021; (41(10)):e0035221 doi:10.1128/MCB.00352-21.
PMID: 34370553
9
Accumulation of ether phospholipids in induced pluripotent stem cells and oligodendrocyte-lineage cells established from patients with Sjögren-Larsson syndrome.
Yamaguchi Y, Okuno H, Tokuoka S, et al.
Congenital anomalies 2025; (65(1)):e12587 doi:10.1111/cga.12587.
PMID: 39617394
10
Disturbed brain ether lipid metabolism and histology in Sjögren-Larsson syndrome.
Staps P, Rizzo WB, Vaz FM, et al.
Journal of inherited metabolic disease 2020; (43(6)):1265-1278 doi:10.1002/jimd.12275.
PMID: 32557630
11
Sjogren-Larsson Syndrome: Mechanisms and Management.
Bindu PS
The application of clinical genetics 2020; (13()):13-24 doi:10.2147/TACG.S193969.
PMID: 32021380
12
Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system.
Roy U, Das U, Pandit A, Debnath A
BMJ case reports 2016; (2016()):10.1136/bcr-2016-215110.
PMID: 27095813
13
Sjögren-Larsson syndrome: definitive diagnosis on magnetic resonance spectroscopy.
Poojary S, Shah M
Cutis 2017; (100(6)):452-455.
PMID: 29360893
14
[Sjögren-Larsson syndrome: Pediatric case report].
García-Ortiz L, Gómez-López R, Rivera-Pedroza CI, et al.
Archivos argentinos de pediatria 2018; (116(6)):e773-e777 doi:10.5546/aap.2018.e773.
PMID: 30457735
15
Sjögren-Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype.
Fouzdar-Jain S, Suh DW, Rizzo WB
Ophthalmic genetics 2019; (40(4)):298-308 doi:10.1080/13816810.2019.1660379.
PMID: 31512987

This page explains the biology and diagnosis of Sjögren-Larsson Syndrome for educational purposes. Always consult your child's geneticist or neurologist to interpret specific laboratory and imaging reports.

Get notified when new evidence is published on Sjögren-Larsson syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents